Literature DB >> 33214697

Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Xin Zhang1,2, Can Hu1,2, Hai-Ming Wu1,2, Zhen-Guo Ma3,4, Qi-Zhu Tang5,6.   

Abstract

Cardiovascular and metabolic diseases are the leading causes of death and disability worldwide and impose a tremendous socioeconomic burden on individuals as well as the healthcare system. Fibronectin type III domain-containing 5 (FNDC5) is a widely distributed transmembrane glycoprotein that can be proteolytically cleaved and secreted as irisin to regulate glycolipid metabolism and cardiovascular homeostasis. In this review, we present the current knowledge on the predictive and therapeutic role of FNDC5 in a variety of cardiovascular and metabolic diseases, such as hypertension, atherosclerosis, ischemic heart disease, arrhythmia, metabolic cardiomyopathy, cardiac remodeling, heart failure, diabetes mellitus, and obesity.
© 2020. CPS and SIMM.

Entities:  

Keywords:  FNDC5; biomarker; cardiovascular and metabolic diseases; therapeutic target

Mesh：

Substances：

Year:  2020        PMID： 33214697      PMCID： PMC8379181          DOI： 10.1038/s41401-020-00557-5

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   7.169


  233 in total

1.  A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues.

Authors:  Suleyman Aydin; Tuncay Kuloglu; Suna Aydin; Mehmet Kalayci; Musa Yilmaz; Tolga Cakmak; Serdal Albayrak; Sami Gungor; Neriman Colakoglu; Ibrahim Hanifi Ozercan
Journal:  Peptides       Date:  2014-09-27       Impact factor: 3.750

2.  Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver.

Authors:  Clémence M Canivet; Stéphanie Bonnafous; Déborah Rousseau; Pierre S Leclere; Sandra Lacas-Gervais; Stéphanie Patouraux; Arnaud Sans; Carmelo Luci; Béatrice Bailly-Maitre; Antonio Iannelli; Albert Tran; Rodolphe Anty; Philippe Gual
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-27       Impact factor: 5.187

3.  Irisin reverses platelet derived growth factor-BB-induced vascular smooth muscle cells phenotype modulation through STAT3 signaling pathway.

Authors:  Haibo Song; Jia Xu; Nan Lv; Yuzhu Zhang; Fei Wu; Huanjie Li; Lei Shao; Qian Mu; Fang Wang; Dongqi Tang; Xu Fang
Journal:  Biochem Biophys Res Commun       Date:  2016-07-11       Impact factor: 3.575

4.  The Levels of Serum Irisin as a Predictor of Insulin Resistance in Han Chinese Adults with Metabolically Healthy Obesity.

Authors:  Bo-Wei Liu; Fu-Zai Yin; Xi-Ming Qi; Dong-Mei Fan; Yue Zhang
Journal:  Clin Lab       Date:  2017-05-01       Impact factor: 1.138

5.  FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity.

Authors:  Xiao-Qing Xiong; Zhi Geng; Bing Zhou; Feng Zhang; Ying Han; Ye-Bo Zhou; Jue-Jin Wang; Xing-Ya Gao; Qi Chen; Yue-Hua Li; Yu-Ming Kang; Guo-Qing Zhu
Journal:  Metabolism       Date:  2018-01-31       Impact factor: 8.694

6.  Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome.

Authors:  Remzi Abali; Ilkbal Temel Yuksel; Mehmet Aytac Yuksel; Berk Bulut; Metehan Imamoglu; Volkan Emirdar; Fehmi Unal; Savas Guzel; Cem Celik
Journal:  J Obstet Gynaecol       Date:  2016-05-16       Impact factor: 1.246

7.  β-arrestin-2 is involved in irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling.

Authors:  Yaling Pang; Haihui Zhu; Jianqin Xu; Lihua Yang; Lingjiao Liu; Jing Li
Journal:  Exp Cell Res       Date:  2017-09-06       Impact factor: 3.905

8.  Association of Serum Irisin Concentrations with Presence and Severity of Coronary Artery Disease.

Authors:  Wen Deng
Journal:  Med Sci Monit       Date:  2016-11-05

9.  Geniposide Protects against Obesity-Related Cardiac Injury through AMPKα- and Sirt1-Dependent Mechanisms.

Authors:  Zhen-Guo Ma; Chun-Yan Kong; Peng Song; Xin Zhang; Yu-Pei Yuan; Qi-Zhu Tang
Journal:  Oxid Med Cell Longev       Date:  2018-11-04       Impact factor: 6.543

Review 10.  The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study.

Authors:  Andrew E Moran; Mohammad H Forouzanfar; Gregory A Roth; George A Mensah; Majid Ezzati; Abraham Flaxman; Christopher J L Murray; Mohsen Naghavi
Journal:  Circulation       Date:  2014-02-26       Impact factor: 29.690
View more
  8 in total

Review 1.  Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).

Authors:  Shuguang Qin; Zhenjun Tian; Maxime Boidin; Benjamin J R Buckley; Dick H J Thijssen; Gregory Y H Lip
Journal:  Front Physiol       Date:  2022-06-29       Impact factor: 4.755

2.  Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus.

Authors:  Alexander A Berezin; Michael Lichtenauer; Elke Boxhammer; Ivan M Fushtey; Alexander E Berezin
Journal:  Front Physiol       Date:  2022-05-16       Impact factor: 4.755

Review 3.  The Effect of Irisin as a Metabolic Regulator and Its Therapeutic Potential for Obesity.

Authors:  Hui Li; Fang Wang; Mu Yang; Jiao Sun; Yi Zhao; Dongqi Tang
Journal:  Int J Endocrinol       Date:  2021-03-18       Impact factor: 2.803

4.  Irisin as a Potential Biomarker Associated with Myocardial Injuries in Patients with Severe Hypothyroidism.

Authors:  Zhi Yao; Xiaoyu Ding; Xia Gao; Ning Yang; Yumei Jia; Jia Liu; Guang Wang
Journal:  Int J Endocrinol       Date:  2021-11-18       Impact factor: 3.257

5.  Fibronectin type III domain-containing 5 improves aging-related cardiac dysfunction in mice.

Authors:  Can Hu; Xin Zhang; Min Hu; Teng Teng; Yu-Pei Yuan; Peng Song; Chun-Yan Kong; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Aging Cell       Date:  2022-02-15       Impact factor: 9.304

6.  MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice.

Authors:  Yuanjie Yu; Tian Tian; Shiyun Tan; Pengbo Wu; Yitian Guo; Ming Li; Mengjun Huang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

7.  Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.

Authors:  Sara Remuzgo-Martínez; Javier Rueda-Gotor; Verónica Pulito-Cueto; Raquel López-Mejías; Alfonso Corrales; Leticia Lera-Gómez; Raquel Pérez-Fernández; Virginia Portilla; Íñigo González-Mazón; Ricardo Blanco; Rosa Expósito; Cristina Mata; Javier Llorca; Vanesa Hernández-Hernández; Carlos Rodríguez-Lozano; Nuria Barbarroja; Rafaela Ortega-Castro; Esther Vicente; Cristina Fernández-Carballido; María Paz Martínez-Vidal; David Castro-Corredor; Joaquín Anino-Fernández; Diana Peiteado; Chamaida Plasencia-Rodríguez; Eva Galíndez-Agirregoikoa; María Luz García-Vivar; Nuria Vegas-Revenga; Irati Urionaguena; Oreste Gualillo; Juan Carlos Quevedo-Abeledo; Santos Castañeda; Iván Ferraz-Amaro; Miguel Á González-Gay; Fernanda Genre
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 8.  Irisin, an Effective Treatment for Cardiovascular Diseases?

Authors:  Chen Liu; Aili Wei; Tianhui Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.